Literature DB >> 11744817

Rapidly progressive glomerulonephritis due to rifampicin therapy.

Keiji Yoshioka1, Norio Satake, Yoshihiro Kasamatsu, Yoshio Nakamura, Nobuaki Shikata.   

Abstract

A 60-year-old man was treated with rifampicin, isoniazid, ethambutol and pyrazinamide for pulmonary tuberculosis. Acute renal failure developed 1 month after re-administration of rifampicin following 1 month's interruption of treatment. A renal biopsy showed crescentic lesions characteristic of rapidly progressive glomerulonephritis. This is, to our knowledge, the fourth case of rapidly progressive crescentic glomerulonephritis associated with rifampicin treatment, which responded to methylprednisolone pulse therapy followed by oral steroid therapy. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11744817     DOI: 10.1159/000046326

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  4 in total

1.  Acute Tubular Necrosis and Thrombocytopenia Associated With Rifampin Use: Case Report and Review.

Authors:  Emma L Smith; Laura Bywater; Rebecca Pellicano; Grant A Jenkin; Tony M Korman
Journal:  Open Forum Infect Dis       Date:  2022-05-17       Impact factor: 4.423

2.  Rifampicin-induced minimal change disease is improved after cessation of rifampicin without steroid therapy.

Authors:  Dong Hyuk Park; Sul A Lee; Hyeon Joo Jeong; Tae-Hyun Yoo; Shin-Wook Kang; Hyung Jung Oh
Journal:  Yonsei Med J       Date:  2015-03       Impact factor: 2.759

3.  Rifampin-associated tubulointersititial nephritis and Fanconi syndrome presenting as hypokalemic paralysis.

Authors:  Hong Ki Min; Eun Oh Kim; Sang Ju Lee; Yoon Kyung Chang; Kwang Sun Suh; Chul Woo Yang; Suk Young Kim; Hyeon Seok Hwang
Journal:  BMC Nephrol       Date:  2013-01-16       Impact factor: 2.388

4.  Rifampicin-Associated Secondary Minimal Change Disease Presenting with Nephrotic Syndrome in a Pulmonary Tuberculosis Patient.

Authors:  Satyanand Sathi; Anil Kumar Garg; Manoj Kumar Singh; Virendra Singh Saini; Devinder Vohra
Journal:  Case Rep Nephrol       Date:  2021-04-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.